(Q42944291)

11 November 2017

title

A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer (English)

1 reference

11 November 2017

A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer (English)

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.496755

17 June 2024

main subject

phase II clinical trial

0 references

metastatic breast cancer

1 reference

1 reference

11

John D Hainsworth

1 reference

11 November 2017

1

Denise A Yardley

1 reference

11 November 2017

Michael McCleod

2

1 reference

11 November 2017

Fred Schreiber

3

1 reference

11 November 2017

Patrick Murphy

4

1 reference

11 November 2017

Jeffrey Patton

5

1 reference

11 November 2017

Mythili Shastry

7

1 reference

11 November 2017

Mark Rubin

8

1 reference

11 November 2017

Marianne Melnik

9

1 reference

11 November 2017

Dana S. Thompson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20690806

17 June 2024

Howard A. Burris

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20690806

17 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20690806

17 June 2024

publication date

1 November 2010

1 reference

full work available at URL

11 November 2017

http://www.tandfonline.com/doi/pdf/10.3109/07357907.2010.496755

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.496755

17 June 2024

1 reference

11 November 2017

volume

28

1 reference

11 November 2017

issue

9

1 reference

11 November 2017

page(s)

925-931

1 reference

VincaAlkaloids in Superacidic Media: A Method for Creating a New Family of Antitumor Derivatives

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Antitumor activity of vinflunine: effector pathways and potential for synergies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Markedly diminished drug resistance-inducing properties of vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Vinflunine, a second generation novel Vinca Alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Antiangiogenic vinflunine affects EB1 localization and microtubule targeting to adhesion sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Vinflunine in the treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Phase II study of vinflunine in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Phase II study of vinflunine in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

A review of vinorelbine in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

A phase II, multicentre, UK study of vinorelbine in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2010.496755

Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro

21 January 2018

3

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.496755

17 June 2024

Molecular Pharmacology

8

53

908

Lobert S.

1998

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.496755

Vinorelbine as single agent in pretreated patients with advanced breast cancer

17 June 2024

18

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.496755

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy

17 June 2024

22

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.496755

Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy

17 June 2024

23

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.496755

Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer

17 June 2024

26

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.496755

Vinorelbine as first-line chemotherapy for metastatic breast carcinoma

17 June 2024

27

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.496755

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer

17 June 2024

30

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.496755

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study

17 June 2024

32

1 reference

https://api.crossref.org/works/10.3109/07357907.2010.496755

17 June 2024

Identifiers

1 reference

11 November 2017

1 reference